29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

      The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
      Antibiotics, Antitubercular, therapeutic use, DNA, Bacterial, analysis, Diagnosis, Differential, False Positive Reactions, HIV, HIV Infections, complications, Humans, Male, Middle Aged, Mycobacterium tuberculosis, drug effects, genetics, isolation & purification, Rifampin, Sputum, microbiology, Tuberculosis, Multidrug-Resistant, diagnosis, drug therapy, Tuberculosis, Pulmonary

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The World Health Organization had endorsed Xpert® MTB/RIF (Xpert) as the initial diagnostic for multidrug-resistant tuberculosis (TB) or TB suspects co-infected with the human immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-susceptible and drug-resistant populations. When decentralising Xpert, test performance characteristics need to be understood by health care workers and methods of confirmation of RMP resistance need to be accessible.

          Related collections

          Author and article information

          Comments

          Comment on this article